Grace Therapeutics (GRCE) Net Income towards Common Stockholders (2019 - 2026)
Grace Therapeutics (GRCE) reported Net Income towards Common Stockholders of -$15.79 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), compared with -$3.36 million a year earlier.
Powered by 
Analysis
Grace Therapeutics (GRCE) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Grace Therapeutics' Net Income towards Common Stockholders came in at -$20.22 million; for FY2026 (ended Mar 31, 2026), it was -$7.79 million.
- By fiscal year, Net Income towards Common Stockholders came in at -$9.57 million in FY2025, -$12.85 million in FY2024, -$42.43 million in FY2023 and -$9.82 million in FY2022.
- The fiscal Q1 2027 figure ranks as the lowest quarterly Net Income towards Common Stockholders since fiscal Q4 2023.
- Per Business Quant data, the three fiscal quarters before Q1 2027 came in at -$1.18 million (Q4 2026), -$2.32 million (Q3 2026) and -$938,000 (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Grace Therapeutics | 33.69 Mn | 33.69 Mn | - | -15.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.79 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -938,000.00 |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | 636,000.00 |
| Dec 31, 2024 | -4.16 Mn |
| Sep 30, 2024 | -3.43 Mn |
| Jun 30, 2024 | -2.62 Mn |
| Mar 31, 2024 | -3.17 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | -3.27 Mn |
| Jun 30, 2023 | -4.02 Mn |
| Mar 31, 2023 | -29.09 Mn |
| Dec 31, 2022 | -3.89 Mn |
| Sep 30, 2022 | -4.93 Mn |
| Jun 30, 2022 | -4.52 Mn |
| Mar 31, 2022 | -3.90 Mn |
| Dec 31, 2021 | -3.78 Mn |
| Sep 30, 2021 | 981,000.00 |
API Access
Grace Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=GRCE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "GRCE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=GRCE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();